Search Results - pharmakodynamic+biomarker

16 Results

Sort By:

Phenotypic Microarray for Diagnosis of Cancer

Invention novelty: High Throughput Screening of pancreatic cancer cells by developing a phenotypic microarray Value Proposition: The market for cancer diagnostics is ever-expanding as the focus of global research on cancer reached its peak in the past five years. The use of microarrays as an ideal diagnostic tool for cancer detection is being realized...

Published: 5/9/2024 | Inventor(s): Denis Wirtz, Pei-Hsun Wu, Shyam Khatau, Wei-Chiang Chen, Zev Binder, Jude Phillip, Yiider Tseng

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics, In Vitro Research Tool, Pharmakodynamic Biomarker, Prognostic Biomarker, Target-based Screening Tool

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics, Technology Classifications > Research Tools > Assays

Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition

TITLEMicrosatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition CASE NUMBER C13241UNMET NEEDThe programmed death 1 (PD-1) pathway is a negative feedback system that represses Th1 cytotoxic immune responses and that, if unregulated, can damage the host. It is up-regulated in many tumors...

Published: 5/9/2024 | Inventor(s): Luis Diaz, Bert Vogelstein, Kenneth Kinzler, Nickolas Papadopoulos, Dung Le, Drew Pardoll, Suzanne Topalian

Keywords(s): Biomarker, Clinical Diagnostics, In Vitro Diagnostics, Pharmakodynamic Biomarker

Category(s): Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics

14-3-3 Mediates a p53-Induced G2 Arrest

C03338: 14-3-3 Mediates a p53-Induced G2 Arrest Technical Details: Exposure of colorectal cancer (CRC) cells to ionizing radiation results in a cell-cycle arrest in G1 and G2. The G1 arrest is due to p53-mediated induction of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/SDI1, but the basis for the G2 arrest is unknown. Through a quantitative...

Published: 5/9/2024 | Inventor(s): Heiko Hermeking, Kenneth Kinzler, Bert Vogelstein

Keywords(s): Biomarker, Cancers, Cell Lines, Cell Signaling, Discovery/Research Tools, Disease Indication, Gene Therapy, Human Cell Lines, In Vitro Research Tool, Molecular Switches/Receptors, Pharmakodynamic Biomarker, Research Reagent, Single, Therapeutic Matter, Therapeutics, Therapy Type, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Technology Classifications > Diagnostics, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities

Genetic Alterations Related to Anti-EGFR Therapeutic Response

Unmet Need:Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are monoclonal antibodies, which prevent epidermal growth factor receptor (EGFR) activation. Several studies have identified alterations in KRAS and other genes...

Published: 5/9/2024 | Inventor(s): Livio Trusolino, Andrea Bertotti, Victor Velculescu, Vilmos Adleff, Eniko Papp

Keywords(s): Biomarker, Cancers, Colorectal Cancer, Disease Indication, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer

Engulfment Gene GULP1 as a Functional Tumor Suppressor in Urothelial Carcinoma

Invention Novelty:The technology identifies a novel biomarker to detect the presence of bladder cancer via a urine test. The technology could be coupled with existing urine-based cancer tests to improve sensitivity as a diagnostic or to test drug efficacy. Value Proposition:Bladder cancer (BC) is the 6th most common cancer in the US, with approximately...

Published: 5/9/2024 | Inventor(s): Mohammad Hoque, Masamichi Hayashi, Elisa Guida

Keywords(s): Biomarker, Bladder Cancer, Cancers, Disease Indication, Epigenetic, Methylation, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics, Urothelial Carcinoma

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Bladder Cancer, Clinical and Disease Specializations > Oncology > Urothelial Carcinoma, Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Urology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Quantitation of GCPII Enzymatic Activity in Human Skin Biopsies as a Clinical Biomarker

We have identified a unique tissue preparation and enzymatic assay conditions to quatitatively monitor glutamate carboxypeptidase II (GCPII) activity in human skin biopsy samples. This assay can be utilzed as a phanacodynamic (PD) marker in the clinical development of novel GCPII inhibitors. This new assay is a significant improvement over GCPII biomarker...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, Camilo Rojas, Marigo Stathis, Michael Polydefkis

Keywords(s): Assay, Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Multiple CNS Indications, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

An Adduct-specific Anti-thymidylate Synthase Antibody for Monitoring Fluorouracil Anticancer Therapy

TITLEAn Adduct-specific Anti-thymidylate Synthase Antibody for Monitoring Fluorouracil Anticancer TherapyCASE NUMBERC11954ABSTRACTWe developed a functional assay for a class of widely used anti-cancer drugs, 5-fluorouracil and related compounds (SFU). It is well established that SFU works largely by inhibiting the enzyme thymidylate synthase (TS) in...

Published: 5/9/2024 | Inventor(s): Kalpeshkumar Patel, Scott Kern

Keywords(s): Antibodies, Biomarker, Cancers, Clinical Diagnostics, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics, Monoclonal Antibodies, Pharmakodynamic Biomarker, Research Reagent

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Diagnostics, Technology Classifications > Research Tools

Method of Assessing Tissue Vascular Permeability Using Non-labeled Dextran Detected by MRI

Novel Strategy to Assess Vascular Permeability for Nanoparticle TherapyJHU REF: C12886Invention Novelty: Use of dextran to assess target tissue vascular permeability and clearance of nanoparticles of various sizes for clinical diagnosis and assessment of appropriate nanoparticle treatment of cancer and other diseases.Value Proposition:Development of...

Published: 5/9/2024 | Inventor(s): Yuguo Li, Peter van Zijl, Guanshu Liu

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Drug Delivery Vehicle, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vitro Diagnostics, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI), Nanoparticles, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Diagnostics, Technology Classifications > Medical Devices, Technology Classifications > Diagnostics > In Vivo Diagnostics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Improved Treatment Prognosis For CancersJHU REF: C12842Invention Novelty:This technology offers a prognostic panel derived from the gene expression of several different cancers, which was validated in multiple primary human samples. The panel, termed "AIM", differentiates patients into two tiers that correspond to a set of suggested treatment...

Published: 5/9/2024 | Inventor(s): Cynthia Zahnow, Stephen Baylin, Angela Guzzetta, Katherine Chiappinelli, Huili Li, Nita Ahuja

Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Combination, Disease Indication, Epithelial Cancer, In Vitro Diagnostics, Non-novel, Pharmakodynamic Biomarker, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Epithelial Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

JHU REF: C12704 - NOVEL STRATEGIES TO OVERCOME MELANOMA DRUG RESISTANCE

Invention novelty: Novel methods for predicting melanoma resistance to BRAF/MEK inhibitors and for treating melanoma cancer patients.Value Proposition:An estimated 76,690 new cases of invasive melanoma will be diagnosed in the US in 2013 and an estimated 9,480 people will die of melanoma in 2013. Although BRAF and MEK inhibitors have proven clinical...

Published: 5/9/2024 | Inventor(s): Dingxie Liu, Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Melanoma, Pharmakodynamic Biomarker, Skin Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

1 2